Dr. Zhao founded Meridian Lab in 2011 and has served as CEO since then. Meridian Lab is a Biopharma company focusing on the cancer treatment including improved formulation and NCE. Its lead products are Polysorbate-80 free docetaxel and cabazitaxel. Before Meridian Lab, Dr. Zhao had had more than 20 years of experiences in clinical development with major pharma companies working on several major NDA submissions and approvals including Celebrex and Prograf. Dr. Zhao has authored and co-authored numerous publications in clinical study design and drug development results. He holds a Ph.D. from University of Illinois at Chicago and a MBA from Kellogg School, Northwestern University.